Shanghai Allist Pharmaceuticals (SHA:688578) will conduct clinical trials on vometinib mesylate tablets after obtaining approval from the Chinese drug administration, according to a Shanghai Stock Exchange.

The drug will be tested as a treatment for patients with lung cancer, the pharmaceutical company said.

The company's shares closed more than 1% in recent trade.